Literature DB >> 25191764

Predicting Risk in Transcatheter Aortic Valve Implantation: Comparative Analysis of EuroSCORE II and Established Risk Stratification Tools.

Miriam Silaschi1, Lenard Conradi1, Moritz Seiffert2, Renate Schnabel2, Gerhard Schön3, Stefan Blankenberg2, Hermann Reichenspurner1, Patrick Diemert2, Hendrik Treede1.   

Abstract

BACKGROUND: The logistic European System for Cardiac Operative Risk Evaluation (logEuroSCORE) II was developed to improve prediction of mortality in cardiac surgery. However, no specific tools are available for risk prediction in transcatheter aortic valve implantation (TAVI). The recently introduced EuroSCORE II was compared with established risk scores. PATIENTS AND METHODS: We assessed 457 consecutive patients (80.5 ± 7.1 years, 52.3% female) undergoing TAVI. Preoperative risk evaluation included logEuroSCORE I, EuroSCORE II, Society of Thoracic Surgeons (STS), Ambler, and Parsonnet scores. Validity was assessed by receiver-operating characteristic (ROC) and area under the curve (AUC).
RESULTS: A 30-day mortality was 9.6% (44/457). Calculated scores were logEuroSCORE I 22.0%, confidence interval (CI) 21.0 to 24.6; EuroSCORE II 7.0%, CI 6.4 to 8.1; STS 7.9%, CI 7.7 to 9.5; Ambler score 6.9%, CI 5.7 to 7.0; and Parsonnet score 23.8%, CI 20.9 to 24.1. ROC analyses demonstrated no predictive value: logEuroSCORE I AUC 0.56, CI 0.47 to 0.65; EuroSCORE II AUC 0.54, CI 0.46 to 0.63; STS AUC 0.57, CI 0.49 to 0.66; Ambler AUC 0.52, CI 0.43 to 0.60; and Parsonnet AUC 0.51, CI 0.43 to 0.60. Accuracy and thresholds were measured on behalf of Youden index. Accuracy ranged between 44.2% (Parsonnet) and 66.3% (logEuroSCORE I). Thresholds were logEuroSCORE I 26%, EuroSCORE II 7%, STS 6%, Ambler 3%, and Parsonnet 19%.
CONCLUSIONS: No risk evaluation system provided acceptable predictive ability. Scores derived from conventional cardiac surgery failed in risk prediction for TAVI. Specific risk tools are required. Until available, estimation of risk has to rely on judgment of an interdisciplinary heart team regarding individual patient factors. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2014        PMID: 25191764     DOI: 10.1055/s-0034-1389107

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  13 in total

1.  Predictive value of preprocedural procalcitonin for short- and long-term mortality after transfemoral transcatheter aortic valve implantation.

Authors:  Stanislav Keranov; Won-Keun Kim; Mani Arsalan; Matthias Renker; Till Keller; Timm Bauer; Oliver Dörr; Holger M Nef; Luise Gaede; Helge Möllmann; Thomas Walther; Christian W Hamm; Christoph Liebetrau
Journal:  Heart Vessels       Date:  2019-06-07       Impact factor: 2.037

2.  Specific biomarkers of myocardial inflammation and remodeling processes as predictors of mortality in high-risk patients undergoing percutaneous mitral valve repair (MitraClip).

Authors:  Oliver Dörr; Claudia Walther; Christoph Liebetrau; Till Keller; Hannes Tabert; Niklas Boeder; Matthias Bayer; Pascal Bauer; Helge Möllmann; Luise Gaede; Christian Troidl; Sandra Voss; Timm Bauer; Christian W Hamm; Holger Nef
Journal:  Clin Cardiol       Date:  2018-04-17       Impact factor: 2.882

3.  Performance of the EuroSCORE II Model in Predicting Short-Term Mortality of General Cardiac Surgery: A Single-Center Study in Taiwan.

Authors:  Pin-Hung Liu; Hsin-Hung Shih; Pei-Leun Kang; Jun-Yen Pan; Tung-Ho Wu; Chieh-Jen Wu
Journal:  Acta Cardiol Sin       Date:  2022-07       Impact factor: 1.800

4.  Evaluation of cystatin C and neutrophil gelatinase-associated lipocalin as predictors of mortality in patients undergoing percutaneous mitral valve repair (MitraClip).

Authors:  Oliver Dörr; Claudia Walther; Christoph Liebetrau; Till Keller; Regine M Ortlieb; Niklas Boeder; Pascal Bauer; Helge Möllmann; Luise Gaede; Christian Troidl; Sandra Voss; Timm Bauer; Christian W Hamm; Holger Nef
Journal:  Clin Cardiol       Date:  2018-11-16       Impact factor: 2.882

Review 5.  Expanding TAVI to Low and Intermediate Risk Patients.

Authors:  Lisa Voigtländer; Moritz Seiffert
Journal:  Front Cardiovasc Med       Date:  2018-07-12

6.  Prognostic Impact of Pre-Transcatheter and Post-Transcatheter Aortic Valve Intervention Troponin: A Large Cohort Study.

Authors:  Mariama Akodad; Marco Spaziano; Bernard Chevalier; Philippe Garot; Hakim Benamer; Annabelle Dinan-Zannier; Xavier Troussier; Thierry Unterseeh; Stéphane Champagne; Thomas Hovasse; Thierry Lefèvre
Journal:  J Am Heart Assoc       Date:  2019-03-19       Impact factor: 5.501

Review 7.  Current results and remaining challenges of trans-catheter aortic valve replacement expansion in intermediate and low risk patients.

Authors:  Alfonso Ielasi; Azeem Latib; Maurizio Tespili; Francesco Donatelli
Journal:  Int J Cardiol Heart Vasc       Date:  2019-05-15

8.  Update and, internal and temporal-validation of the FRANCE-2 and ACC-TAVI early-mortality prediction models for Transcatheter Aortic Valve Implantation (TAVI) using data from the Netherlands heart registration (NHR).

Authors:  Hatem Al-Farra; Bas A J M de Mol; Anita C J Ravelli; W J P P Ter Burg; Saskia Houterman; José P S Henriques; Ameen Abu-Hanna; M M Vis; J Vos; L Timmers; W A L Tonino; C E Schotborgh; V Roolvink; F Porta; M G Stoel; S Kats; G Amoroso; H W van der Werf; P R Stella; P de Jaegere
Journal:  Int J Cardiol Heart Vasc       Date:  2021-01-23

9.  Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis.

Authors:  Gary Tse; Christina Ip; King Sum Luk; Mengqi Gong; Yan Yee Ting; Ishan Lakhani; George Bazoukis; Guangping Li; Konstantinos P Letsas; Mei Dong; Tong Liu; Martin C S Wong
Journal:  Heart Asia       Date:  2018-03-06

10.  Clinical value of the 20% logistic EuroSCORE cut-off for selecting TAVI candidates: a single-centre cohort study analysis.

Authors:  Guram Imnadze; Steffen Hofmann; Michael Billion; Abbas Ferdosi; Marek Kowalski; Ehab Rajab; Karin Bramlage; Peter Bramlage; Henning Warnecke; Norbert Franz
Journal:  Open Heart       Date:  2020-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.